IL17A and nasopharyngitis: Besides, the most common adverse reactions of IL-17 inhibitors in psoriasis and psoriatic arthritis patients were as follows: Infection (33.16%), nasopharyngitis (13.74%), and injection site reactions (8.28%) [90].